| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.4 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.4 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.06 | 0.4 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |